reMYND in €350m diabetes deal with Novo Belgian reMYND N.V. has out licenced worldwide commercialisation rights for its small molecule programme ReS39 in diabetes to Novo Nordisk A/S. The drug impedes death of insulin-producing beta cells … more ➔
TB urine test outperforms standard of careA new, non-invasive tuberculosis urine test prevents common disadvantages of the standard tuberculin skin test: Measuring lipoarabinomannan glycan from M. tuberculosis, it detects the active disease … more ➔
LSP raises €280m for late-stage med-tech...Life sciences investment group LSP has launched the largest fund in Europe dedicated to late-stage medical technology assets, including diagnostics and digital health. more ➔
Aelin Therapeutics NV bags €27m in Serie...Belgian start-up company Aelin Therapeutics NV secured the funds to push development of candidate drugs arising from its Pept-in protein knockdown platform, which harnesses protein aggregation to induce … more ➔
ArgenX reports hints to efficacy of ARGX-1...Dutch llama antibody specialist ArgenX met the safety endpoint in a Phase II trial with ARGX 113 (efgartigimod), a first-in-class antibody that lowers pathogenic levels of IgG, in patients with the autoimmune … more ➔
Ortho markets predictive heart failure re-...In vitro diagnostics leader Ortho Clinical Diagnostics (Raritan, US) expands his assay portfolio with Sphingotec’s first-in-class biomarker test that predicts residual edema and re-hospitalization in … more ➔
Advicenne raised a €27m IPO on Euronext...French based Advicenne has raised a €27m IPO on Euronext Paris, to develop paediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases. more ➔
Researchers create druggable “love h...A European-Australian team of researchers has created a synthetic version of oxytocin that does not show the off-target effects mediated by its chemical analogon vasopressin. more ➔
FDA approves pan-tumour genomic profiling... Roche company Foundation Medicine Inc. (FMI) has been granted FDA approval for a diagnostic multiplex tumour profiling assay, which identifies a broad range of tumour markers in one single measurement. more ➔
Sanofi Pasteur ends Clostridium difficile...The decision of the vaccine arm of French drug giant Sanofi was based on an independent interim analysis of a pivotal Phase III study enroling up to 16,500 people at risk of Clostridium difficile infection … more ➔
